Potent and selective ligands for the dopamine transporter (DAT): Structure-activity relationship studies of novel 4-[2- (diphenylmethoxy)ethyl]-1-(3-phenylpropyl)piperidine analogues

Journal of Medicinal Chemistry

Volumn 41, Issue 5, 1998, Pages 699-705

  Dutta, Aloke K ^a   Coffey, Lori L ^b   Reith, Maarten E A ^b  

^a ORGANIX INC   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 (DIPHENYLMETHOXY)ETHYL] 1 [3 (4' FLUOROPHENYL)PROPYL)PIPERIDINE; DOPAMINE TRANSPORTER; PIPERIDINE DERIVATIVE; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; VANOXERINE;

ANIMAL TISSUE; ARTICLE; BRAIN MEMBRANE; CORPUS STRIATUM; DRUG ACTIVITY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZHYDRYL COMPOUNDS; CARRIER PROTEINS; CELL MEMBRANE; COCAINE; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MOLECULAR STRUCTURE; NERVE TISSUE PROTEINS; PIPERAZINES; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032567986     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970595h     Document Type: Article

References (36)

1. Musto, D. F. Opium, cocaine and marijuana in american history. Sci. Am. 1991, 256, 40-47.
2. Clouet, D., Ashgar, K., Brown, R., Eds. Mechanism of Cocaine Abuse and Toxicity; NIDA Research Monograph; NIDA; 1988; p 88.
3. Johanson, C. E.; Fischman, M. W. The pharmacology of cocaine related to its abuse. Pharmacol. Rev. 1989, 41 (1), 3-52.
4. Reith, M. E. A.; Meisler, B. E.; Sershen, H.; Lajtha, A. Structural requirements for cocaine congeners to interact with dopamine and serotonin uptake sites in mouse brain and to induced stereotyped behavior. Biochem. Pharmacol. 1986, 35, 1123- 1129.
5. Ritz, M. C.; Cone, E. J.; Kuhar, M. J. Cocaine inhibition of ligand binding at dopamine, norpinephrine and serotonin transporters: A structure-activity study. Life Sci. 1990, 46, 635-645.
6. 3H]Mazindol binding associated with neuronal dopamine and norepinephrine uptake sites. Mol. Pharmacol. 1984, 26, 35-44.
7. Kuhar, M. J.; Ritz, M. C.; Boja, J. W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci. 1991, 14, 299-302.
8. Robinson, T.; Barridge, K. C. The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Res. Rev. 1993, 18, 249-291.
9. Ritz, M. C.; Lamb, R. J.; Goldberg, R.; Kuhar, M. J. Cocaine receptors on dopamine transporters are related to self-adminstration of cocaine. Science 1987, 237, 1219-1223.
10. Giros, B.; Jaber, M.; Jones, S. R.; Wightman, R. M.; Caron, M. G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996, 379, 606-612.
11. Carroll, F. I.; Lewin, A. H.; Boja, J. W.; Kuhar, M. J. Cocaine receptor: Biochemical characterization and structure-activity relationship of cocaine analogues at the dopamine transporter. J. Med. Chem. 1992, 35, 969-981.
12. Chaudieu, I.; Vignon, J.; Chicheportiche, M.; Kamenka, J.-M.; Trouiller, G.; Chicheportiche, R. Role of the aromatic group in the inhibition of phencyclidine binding and dopamine uptake by PCP analogues. Pharmacol. Biochem. Behav. 1989, 32, 699- 705.
13. Van der Zee, P.; Koger, H. S.; Gootjes, J.; Hespe, W. Aryl 1,4-dialk(en)ylpiperazines as selective and very potent inhibitors of dopamine uptake. Eur. J. Med. Chem. 1980, 15, 363-370.
14. Clarke, R. L.; Daum, S. J.; Gambino, A. J.; Aceto, M. D.; Pearl, J.; Levitt, M.; Cumiskey, W. R.; Bogado, E. F. Compounds affecting the central nervous system. 4. 3β-Phenyltropane-2- carboxylic esters and analogues. J. Med. Chem. 1973, 16, 1260- 1267.
15. Meltzer, P. C.; Liang, A. Y.; Madras, B. K. The discovery of an unusually selective and novel cocaine analog: Difluoropine. Synthesis and inhibition of binding at cocaine recognition sites. J. Med. Chem. 1994, 37, 2001-2010.
16. Kotian, P.; Mascarella, S. W.; Abraham, P.; Lewin, A. H.; Boja, J. W.; Kuhar, M. J.; Carroll, F. I. Synthesis, ligand binding, and quantitative structure-activity relationship study of 3β-(4′- substituted phenyl)-2β-(heterocyclic)tropanes: Evidence for an electrostatic interaction at the 2β-position. J. Med. Chem. 1996, 39, 2753-2763.
17. 3H]GBR 12935 binding in vitro to rat striatal membranes: Labeling of the dopamine uptake complex. J. Neurochem. 1987, 48, 1887-1896.
18. Anderson, P. H. The dopamine uptake inhibitor GBR 12909: Selectivity and molecular mechanism of action. Eur. J. Pharmacol. 1989, 166, 493-504.
19. Rothman, R. B.; Grieg, N.; Kim, A.; de Costa, B. R.; Rice, K. C.; Carrol, F. I.; Pert, A. Cocaine and GBR 12909 produce equivalent motoric responses at different occupancy of the dopamine transporter. Pharmacol. Biochem. Behav. 1992, 43, 1135-1142.
20. Glowa, J. R.; Wojnicki, F. H. E.; Matecka, D.; Bacher, J. D.; Mansbach, R. S.; Balster, R. L.; Rice, K. C. Effects of dopamine reuptake inhibitors on food- and cocaine-maintained responding: I. Dependence on unit dose of cocaine. Exp. Clin. Psychopharmacol. 1995, 3, 219-231.
21. Glowa, J. R.; Wojnicki, F. H. E.; Matecka, D.; Rice, K. C.; Rothman, R. B. Effects of dopamine reuptake inhibitors on food- and cocaine-maintained responding: II. Comparisons with other drugs and repeated administrations. Exp. Clin. Psychopharmacol. 1995, 3, 232-239.
22. Sogaard, U.; Michalow, J.; Butler, B.; Lund Laursen, A.; Ingersen, S. H.; Skrumsager, B. K.; Rafaelsen, O. J. A tolerance study of single and multiple dosing of the selective dopamine uptake inhibitor GBR 12909 in healthy subjects. Int. Clin. Psychopharm. 1990, 5, 237-251.
23. Rothman, R. B.; Mele, A.; Reid, A. A.; Akunne, H. C.; Greig, N.; Thurkauf, A.; de Costa, B. R.; Rice, K. C.; Pert, A. GBR 12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. Pharmacol. Biochem. Behav. 1991, 40, 387-397.
24. Dutta, A. K.; Meltzer, P. C.; Madras, B. K Positional importance of the nitrogen atom in novel piperidine analogues of GBR 12909: Affinity and selectivity for the dopamine transporter. Med. Chem. Res. 1993, 3, 209-222.
25. Dutta, A. K.; Xu, C.; Reith, M. E. A. Structure-Activity Relationship Studies of Novel 4-[2-[Bis(4-fluorophenyl)methoxy]-ethyl]-1-(3-phenylpropyl)piperidine analogues: Synthesis and biological evaluation at the dopamine and serotonin transporter sites. J. Med. Chem. 1996, 39, 749-756.
26. Dutta, A. K.; Coffey, L. L.; Reith, M. E. A. Highly selective, novel analogues of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine for the dopamine transporter: Effect of different aromatic substitutions on their affinity and selectivity. J. Med. Chem. 1997, 40, 35-43.
27. Madras, B. K.; Reith, M. E. A.; Meltzer, P. C.; Dutta, A. K. O-526, a piperidine analogue of GBR 12909, retains high affinity for the dopamine transporter in monkey caudate-putamen. Eur. J. Pharmacol. 1994, 267, 167-173.
28. Deutsch, H. M.; Schweri, M. M.; Culbertson, C. T.; Zalkow, L. H. Synthesis and pharmacology of irreversible affinity labels as potential cocaine antagonists: Aryl 1,4-dialkylpiperazines related to GBR-12783. Eur. J. Pharmacol. 1992, 220, 173-180.
29. Matecka, D.; Lewis, D.; Rothman, R. B.; Dersch, C. M.; Wojnicki, F. H. E.; Glowa, J. R.; DeVries, C.; Pert, A.; Rice, K. C. Heteroaromatic analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as high-affinity dopamine reuptake inhibitors. J. Med. Chem. 1997, 40, 705-716.
30. Matecka, D.; Rice, K. C.; Rothman, R. B.; De Costa, B.; Glowa, J. R.; Wojnicki, F. H.; Pert, A.; George, C.; Carroll, F. I.; Silverthorn, M. L.; Dersch, C. M.; Becketts, K. M.; Partilla, J. S. Synthesis and absolute configuration of chiral piperazines related to GBR 12909 as dopamine reuptake inhibitors. Med. Chem. Res. 1994, 5, 43-53.
31. Matecka, D.; Rothman, R. B.; Radesca, L.; De Costa, B.; Dersch, C. M.; Partilla, J. S.; Pert, A.; Glowa, J. R.; Wojnicki, F. H.; Rice, K. C. Development of novel, potent, and selective dopamine reuptake inhibitors through alteration of the piperazine ring of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[Bis(4-fluorophenyl)- methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909). J. Med. Chem. 1996, 39, 4704-4716.
32. Meltzer, P. C.; Liang, A. Y.; Madras, B. K. 2-Carbomethoxy-3- (diarylmethoxy)-1αH,5αH-tropane analogues: Synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series. J. Med. Chem. 1996, 39, 371-379.
33. Kline, R. H.; Izenwasser, S.; Katz, J. L.; Joseph, D. B.; Bowen, W. D.; Newman, A. H. 3′-Chloro-3α-(diphenylmethoxy)tropane but not 4′-chloro-3α-(diphenylmethoxy)tropane produces a cocaine- like behavioral profile. J. Med. Chem. 1997, 40, 851-857.
34. Curtin, D. Y.; Leskowitz, S. Cleavage and rearrangement of ethers with base. II. reaction of the benzhydryl and trityl ethers of benzoin with potassium hydroxide. J. Am. Chem. Soc. 1951, 73, 2633-2636.
35. Borch, R. F.; Bernstein, M. D.; Durst, H. D. The cyanohydridoborate anion as a selective reducing agent. J. Am. Chem. Soc. 1971, 93, 2897-2904.
36. Burger, A. Isosterism and bioisosterism in drug design. Prog. Drug. Res. 1991, 37, 287-371.